CSL

View our library:

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Notable Podcast: Drug Fix: US FDA Versus Moderna And The Changing Role Of Refuse To File Actions
• Notable Webinar: Design to Recruit: Connecting Feasibility and Patient Recruitment (4pm GMT, March 18 | Register)
• Notable Webinar: Orphan Drugs: A Safe(r) Passage Amid Stormy Waters? (3pm GMT, March 17 | Register)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• Notable M&A: Gilead Sciences to Acquire Partner Arcellx for $7.8B
• Notable M&A: Masimo to be Acquired by Danaher for $180.00 Per Share ($9.9B)
• Notable Licensing: Astellas, Vir Biotechnology Enter Global Collaboration For VIR-5500 totalling $1.7B ($315M upfront)
• Notable Licensing: Innovent Enters Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology totalling $8.8B ($350M upfront)
• Notable Financing: Generate Biomedicines Nets $374M in IPO
• Notable Financing: Slate Medicines Raises $130M in Series A Round

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Notable Analysis: AstraZeneca | Breztri Aerosphere delivering promising Phase III results in asthma trial may face an uphill commercial battle
• Notable Analysis: Spruce Biosciences | Spruce reports positive FDA Type B meetings for TA ERT and moves anticipated BLA submission to Q4 2026
• Notable Analysis: Incyte Corp. | FIGHT-209 termination highlights limited efficacy of single-agent FGFR inhibition in recurrent glioblastoma
• Notable Analysis: Protara Therapeutics | TARA-002 falls short of expectations in BCG-unresponsive patients in the ADVANCED-2 trial
• Notable Analysis: BioMarin Pharma | Hemophilia A gene therapy Roctavian withdrawn from the market
• Notable Analysis: Pharming Group | FDA issues complete response letter for Pharming’s Joenja pediatric sNDA, citing dosing and manufacturing concerns

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Notable Report: Dealmaking & Financing Quarterly Statistics, Q4 2025
• Notable Report: 2026 Biopharma Financing Focus: The Data, Deals and Discipline Reshaping Growth
• Notable Report: Clinical Disclosure in 2026: How Misalignment Impacts Company Valuation and Litigation Risk
• Notable Report: The State of Clinical Trial Transparency: 2025 Developments and 2026 Predictions
• Notable Report: Earning Their Trust: Challenges and Best Practices in Rare Disease Patient Recruitment
• Notable Report: The AI Reform of Clinical Trials: How Biopharma Benefits
• Notable Report: Epidemiology & Market Forecast - Atopic Dermatitis | Cystic Fibrosis | Duchenne Muscular Dystrophy
• Notable Report: KOL Interview - Atopic Dermatitis | Autism Spectrum | Duchenne Muscular Dystrophy | Dry AWD | Neuroendocrine Tumors | Sjögren’s Disease

Note: Require research support on scientific meetings not under below list? Submit your inquiry via Ask the Analyst!